Fri.Sep 23, 2016

Remove blogging-develop
article thumbnail

Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More

Xconomy

Allergan also bought Akarna Therapeutics, another NASH drug developer, for a much smaller sum. —Roche’s Genentech division is paying Germany’s BioNTech $310 million in upfront and near-term milestones to co-develop cancer vaccines. based skin drug developer Novan (NASDAQ: NOVN ) raised $45 million in its IPO.